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Abstract  
Many novel therapies are available for use in metastatic castrate resistant prostate 
cancer (mCRPC), some of which convey significant progression-free and overall survival 
benefits. Delaying progression and palliation of symptoms are primary therapeutic aims, 
so it is vital to ensure that benefit/harm ratios are acceptable through systematic 
measurement of patient reported outcomes (PROs) using validated tools. We appraised 
mCRPC clinical trial publications over the past 5 years and found that PROs were either 
not being measured routinely or often failed to be reported adequately hampering 
evaluation. Improvements are needed as data collected directly from patients, not just 
physician collected safety data and adverse events, are crucial to inform decision-
making about treatment options. 
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Introduction 
The most common non-cutaneous cancer affecting men is prostate cancer; it is the 
second commonest cause of cancer-related death in the US and the third in Europe1. 
Approximately 25-30% of men who initially present with localised or locally advanced 
disease will have a recurrence and many will require systemic treatment with androgen 
deprivation therapy (ADT). ADT can control the disease for some years but the prostate 
cancer ultimately progresses and requires the addition of different therapeutic 
approaches. Unfortunately the majority, who present with advanced or metastatic 
prostate cancer, will progress to this stage of castrate resistant prostate cancer (CRPC) 
despite an initial response to ADT.2 
The most common first line chemotherapy treatment for metastatic CRPC (mCRPC) is 
docetaxel plus prednisone.3 Additional more novel agents have expanded the treatment 
options including radium-223 dichloride [Ra223], and Sipuleucel-T (an autologous 
cellular immunotherapy).4,5  Advancing prostate cancer is not uniformly refractory to 
further hormonal manipulation and androgens, and disease progression is frequently 
dependent on androgen synthesis and androgen receptor interactions. CRPC which is 
still hormone sensitive, has been clearly characterised by its response to new drugs such 
as abiraterone acetate (androgen biosynthesis inhibitor) and enzalutamide (androgen 
receptor inhibitor). These compounds have demonstrated survival benefits for patients in 
Phase III clinical trials in the docetaxel naïve setting and also in men who have 
progressed after chemotherapy.6-9 Second line chemotherapy with cabazitaxel has also 
demonstrated benefits in overall survival when compared with mitoxantrone.2 
Many have raised concerns about the infinite demands being made on finite healthcare 
budgets. Cancer drugs in particular have come under intense scrutiny as they are 
invariably expensive and their actual benefits to patients, let alone society, are often 
incompletely measured and poorly elucidated. Increasing numbers of men globally have 
mCRPC and want access to novel therapies, which although approved may not be 
available having failed health technology assessments. Traditional clinical outcomes 
such as Progression Free Survival (PFS) and Overall Survival (OS) are well measured in 
trials but patient perspectives less so.  Frequently the quality of the evidence and 
knowledge available about issues other than survival that might influence decision 
makers is inadequate. There is still far too great reliance placed on clinician adverse 
event (AE) recording within trials rather than directly from patients and thus many side-
effects go under-reported, under-recognised and under-treated. Not only is the reliability 
of AE reporting between clinicians poor10  but patients record many symptoms more 
frequently and at a greater severity than ratings made by clinicians using CTCAE 
(Common Terminology Criteria for Adverse Events) criteria.11 Certain side effects may 
have far more relevance to the decision making process of men than is realised, for 
example what may be termed relatively minor symptoms by a clinician may in fact have a 
profound effect on certain individuals and strongly influence their treatment choices.12 
Men with mCRPC report significantly poorer quality of life (QoL) than other groups of 
men with prostate cancer with priority areas being fatigue, pain, and decreased physical 
activity.13 From the patient’s perspective, optimal treatment for advanced prostate cancer 
may be a function of the patient’s willingness to make trade-offs between attributes such 
as efficacy and tolerability. Treatment choices involve complex decision-making that 
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might not always appear rational to a clinical scientist. Even when the information 
provided is optimal, individual patients may have preferences influenced by expectations 
about their likely ability to continue to pursue hobbies, employment, and other activities. 
Again hard data regarding these salient issues from a patient’s perspective are often 
missing. The experience and acceptability of treatment may be linked to the expectations 
about therapeutic intent, likely side-effects and trade-offs between these and control of 
the cancer, which in turn may be determined by the information provided by Health Care 
Professionals (HCPs). The knowledge and perceptions HCPs themselves may have 
about the impact of treatments on more patient related concerns is uncertain, especially 
if QoL type data are generally unavailable.14 To this end, The American Society of 
Cancer Oncology (ASCO) and its European counterpart (ESMO) have published papers 
this year suggesting that new scales are needed to determine the magnitude of clinical 
benefit from a patient’s perspective. 15,16 
Patient reported outcome measures (PROMs) 
Both the US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) have recognised that good quality data from PROMs are important when 
evaluating drugs in patients for whom palliation of symptoms is an important therapeutic 
goal; consequently they have published guidance and recommendations for use of 
PROMs in clinical trials.17 18  Despite this, evidence from ClinicalTrials.gov (2007–2013) 
identified only 29% (3947/13,584) of all oncology trials as using one or more PROM and 
merely 2453/13, 584 (18%) of oncology trials listed a PRO as a primary or secondary 
outcome.19 Although these figures showed an increase since the FDA PRO guidelines 
publication, the omission of PROs is a sorry reflection on the value placed on such 
measures. 
We wished to critique publications over the past 5 years, of mCRPC treatment trials 
where the therapeutic aims are control of progression and amelioration of symptoms of 
disease. We wanted to see if studies had included good quality PRO data. Our approach 
was not a systematic review, but we did use criteria similar to those specified by Clavert 
and colleagues when making some evaluation of the quality. 20 We considered 5 areas:- 
(1) identification of PROs as a primary or secondary outcome (2) hypothesis and 
relevant domains described (3) evidence provided or cited of the validity and reliability of 
the PRO (4) explicit statements about statistical approaches for dealing with missing 
data and (5) some discussion about PRO–specific limitations of study 
findings/generalisability of results to other populations and clinical practice. For us to 
consider the reports to be examples of good quality, they had to cover at least 4 of these 
quality areas and demonstrate convincingly that the investigational drug had improved 
QoL or pain outcomes as well as efficacy. We deemed publications as adequate if only 3 
areas were covered, and poor if any improvements were not compelling and/or 2 or 
fewer key areas were mentioned. 
 
      Effects of mCRPC treatments on QoL and pain palliation 
The types of patient reported outcome measures that were used in the recent mCRPC 
treatment trials we accessed are shown in Table 1.   
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Table 2 lists the reported effects of mCRPC treatments on QoL and pain palliation by 
drug. 
Enzalutamide 
Trials that have been well conducted as far as PROs are concerned include two 
assessing enzalutamide. Fizazi and colleagues21 reported the clinical endpoints and 
overall QoL for the AFFIRM trial but more detailed QoL analyses were provided in a 
separate publication by Cella and colleagues22 and showed that enzalutamide 
significantly improved QoL. Following 25 weeks of treatment the mean FACT-P total 
score decreased by 1.52 points with enzalutamide compared with 13.73 points with 
placebo (p<0.001), reflecting a larger deterioration in the QoL of those men receiving 
placebo. In addition there were significant treatment differences favouring enzalutamide 
for all FACT-P subscales and indices, including pain, whether analysed by mixed effects 
model for repeated measures that assumes missing data are at random, or a pattern 
mixed model that assumes missing data are not at random.  
In the PREVAIL trial QoL and pain were measured at baseline with the FACT-P, EQ5-D 
and the BPI-SF and thereafter at regular periods throughout study treatment.23 
Improvement in QoL was defined as an increase, and deterioration as a decrease, in the 
score at any post baseline assessment by pre -determined thresholds. These thresholds 
were based on score range changes that are clinically meaningful to patients. The 
authors detailed succinctly the components of the questionnaires in a table for ease of 
reference. The results showed that enzalutamide was associated with reduced risk of, 
and delayed time to QoL deterioration, pain progression and occurrence of SREs. 
Abiraterone 
There are a comprehensive series of publications reporting PROs in the Phase III COU-
AA-301 RCT a double blind placebo controlled trial of abiraterone + prednisone versus 
placebo + prednisone. The pain, QoL and fatigue analyses were all published separately. 
24-26 Pain was assessed using the BPI-SF at baseline, day 15 of cycle 1 and day 1 of 
each treatment cycle thereafter until discontinuation. Analgesia use was measured and 
time to occurrence of each skeletal-related event (SRE). Completion rates of the 
questionnaires were reasonably good and the authors used prospectively defined 
response criteria. Pain palliation was assessed in those who had clinically significant 
baseline pain, whereas all other analyses were done on an overall intention to treat 
analysis. The trial results showed that abiraterone + prednisone produced significant 
pain palliation and faster pain palliation in patients with clinically significant pain at 
baseline as well as delaying time to first SRE 24. Harland and colleagues reported the 
QoL data from the same trial using the FACT-P 25. The analysis was performed only in 
those patients with clinically significant functional impairment at baseline on the basis 
that they could not evidence any improvement in QoL. Arguably a clearer picture of how 
the drugs affect QoL may have been achieved if a responder analysis showing the 
proportion of patients who improved, deteriorated or stayed the same over time had 
been done. Significant improvements on the FACT-P total score in favour of abiraterone 
were noted (p<0.0001), including all subscale scores, apart from social/family well-being. 
Sternberg and colleagues26 described the fatigue results from the same study using the 
Brief Fatigue Inventory. The questionnaire was completed at baseline (approximately 14 
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days before the first dose of study treatment) and on the first day of each treatment cycle 
until treatment was discontinued.  Clinically meaningful changes were pre-specified 
before conducting the analyses and similar to Harland25, analyses were confined to 
those with significant clinical fatigue at baseline (i.e. scores of > 5). The report 
demonstrated that abiraterone acetate and prednisone provide substantial and 
meaningful improvements in self-report fatigue in patients with mCRPC after docetaxel 
chemotherapy.26 
Basch and colleagues used the FACT-P and BPI-SF to examine QoL and pain palliation 
respectively in the Phase III trial COU-AA-302 (abiraterone acetate plus prednisone 
versus prednisone alone in chemotherapy-naive men with mCRPC) 27. The pain analyses 
were detailed, and showed that abiraterone and prednisone delayed time to progression 
of mean pain intensity and pain interference as well as time to QoL deterioration. 
In summary all these publications together showed an advantage of aberiterone and 
prednisone to patients in terms of efficacy, pain control and QoL. 
Docetaxel 
The Phase II trial of docetaxel +/- estramustine reported results from the EORTC QLQ 
C30, BPI and analgesia use. 28 Data from 59/79 patients were included in the analysis. 
The authors reported the proportions of patients who improved, remained stable or 
worsened from baseline, and there were no significant changes in the EORTC-QLQ C30 
scales or pain scores during treatment. Probably the most interestingly feature of this 
study was the finding that the baseline QoL measurements appeared to predict 
treatment responders from non-responders.  
A publication of an RCT in which men received either continuous (n=75) or monthly 
intermittent (n=73) docetaxel treatment failed to show any significant differences in QoL 
(EORTC QLQ C-30) or pain (BPI-SF).  However this may have been due to the timing of 
the assessments. Despite QoL being cited as the primary outcome of the study the 
publication lacks important details about missing data and how the analyses were 
conducted. 29  
Cabazitaxel 
The TROPIC trial was a prospective Phase III RCT that involved 755 mCRPC patients 
who had progressed during or after docetaxel based chemotherapy. 2 Follow-up pain and 
QoL data were measured retrospectively with the McGill-Melzack pain questionnaire in a 
sub group of patients who had survived for 2 years.30   The ECOG score was employed 
as a QoL measure; however this is not a PRO, rather a performance score which is 
assessed and completed by the clinician. The sample size was small, there was poor 
reporting of pain data and unsurprisingly no significant differences were found between 
groups. 
In a follow on Phase III/IV trial to facilitate access to cabazitaxel and evaluate more 
formally QoL, 112 men with mCRPC completed the EQ5D with the general ‘health today’ 
VAS at baseline, following alternate cycles and at the end of treatment.31 The choice of 
this instrument (used predominantly to provide a utility score for use in health economic 
models) limited the ability to collect comprehensive information about any toxicities from 
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a patient’s perspective and few formal analyses were carried out despite the claim of a 
trend to significant improvement in QoL. 
Radium-233 chloride 
Pain palliation was the primary endpoint in the Phase II trial of radium-233 chloride, in 
which patients were randomised to a single intravenous dose of 5, 25, 50 or 100kBq/kg 
radium-233.32 The effect of the treatment was documented by patients’ self-assessment 
of pain using a VAS, the BPI and analgesia use. As is the case with many studies of 
patients with metastatic disease, few patients from the original sample survive for follow 
up; at 12 months data were available on 32/100 and 8/100 at 24 months. The primary 
endpoint pain index (VAS and analgesia use) was used to classify patients as pain 
responders or non-responders. Results showed that up to 71% of patients had a pain 
response at week 8 after a single radium injection. Small numbers and incomplete follow 
up limit generalisability of results. 
177Lu-EDTMP 
Agarwal and colleagues examined in a Phase II RCT trial high v low dose 177Lu-EDTMP 
for bone pain relief in patients with bone metastases (N=32 mCRPC; N=12 breast).33 
They used the McCaffery VAS to measure pain, and the Karnofsky Performance Score 
(KPS) for QoL. Pain relief was assessed in terms of changes in average baseline pain v 
average scores at 1,2,4,5,7,12 and 16 weeks. They reported a progressive decrease in 
pain on the VAS from baseline up to 4 weeks, and claimed an improvement in QoL. 
However the KPS is not a PRO measure but a clinician completed performance scale 
originally designed to determine nursing workload and staffing requirements. 
Denosumab 
The final paper reports results from a pooled analysis from three identically designed 
double blind Phase III studies comparing subcutaneous denosumab with intravenous 
zolendronic acid in 5,544 patients with bone metastases, 1,901 of whom were men with 
mCRPC.34 Analysis of the data showed that denosumab significantly delayed time to an 
increase in pain severity in those with pain at baseline and delayed pain for those with no 
/mild pain at baseline. Although the statistics are very thorough, the pooled analyses 
make it hard to determine benefits for the prostate patients alone. 
Conclusions/perspectives 
The increasing numbers of therapeutic endeavours to improve the outlook for men with 
mCRPC is welcome. Unfortunately there are still insufficient patient outcome data from 
trials. Importantly even less is known about the impact of novel therapies when used in 
other clinical settings where patients may have co-morbidities and characteristics that 
make them ineligible for treatment within a trial. Routine collection of a standard set of 
outcomes such as those recommended for prostate cancer trials35 or more recently 
others developed by the ICHOM group 36, which come directly from patients in clinic, 
might be invaluable to build up sufficient ‘real-world’ data to aid decision-making. 
Discussion 
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Both disease burden and mCRPC treatments can have a deleterious impact upon QoL.  
Pain is the most frequently observed symptom in men with mCRPC and appropriate 
analgesia is often underutilised.13,37  In comparison to other men with prostate cancer, 
those with mCRPC report significantly poorer QoL, due to pain, fatigue, and decreased 
physical activity.38 These areas of concern need to be captured  fully when palliation is a 
therapeutic aim.  PROs have been included in more recent treatment trials but usually as 
secondary endpoints with the exception of the Phase II studies. 29, 32, 33   Several articles 
contained opaque, post-hoc exploratory analyses with little or no clear evidence that the 
patient reported endpoints chosen had been established a priori. Much of the published 
work was characterised by inappropriate choice of instruments, poor statistical analyses 
or scanty reporting and inadequate interpretation of results. The statistical analyses in 
papers scrutinised included comparisons of mean scores at one time-point and no 
references to changes from baseline, to responder analyses and cumulative distribution 
function plots. Not all reports determined or utilised the published minimally important 
differences (MIDs) or clinically meaningful differences when comparing any changes in 
scores. Details about the handling of missing data, any imputation used, and sensitivity 
analysis to test if data were truly missing at random and ignorable were seen in 
remarkably few studies. 
The variable quality of the analyses and reporting was often dependent as to whether or 
not PROs had been written up separately from the main efficacy papers in 
comprehensive publications such as those from the COU-AA-301 studies. 24-26   This is of 
course a dilemma when many researchers and journals give priority to papers containing 
more traditional safety data and adverse event reporting leaving little space for 
secondary endpoints such as PROs. 
The continued dearth of quality PRO data from patients for whom palliation of symptoms 
is essential is both disappointing and surprising. The European Medicines Agency (EMA) 
provides broad recommendations on HRQoL (Health Related Quality of Life) in the 
context of clinical trials. 18  and the US Food and Drug Administration (FDA) has formal 
guidance setting standards for use of PROMs in support of product labelling claims.17 An 
interesting paper published recently explored the reasons for rejection of PRO label 
claims among new molecular and biological license applications. It revealed that the FDA 
specifically questioned the content validity and/or validity of instruments in general, and 
there were often issues with the study design, data quality, or interpretation of results.38  
Many novel products in the past decade have been shown to extend the lives of men 
with mCRPC but if they and their physicians are to make wise decisions about 
management options to the harms and putative benefits derived from different 
treatments must be addressed more adequately. Researchers need to employ well-
validated, appropriate PRO measures in trials and to analyse and report the results more 
fully. 
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Table 1: Patient Reported Outcome Measures used in recent mCRPC publications 
Measure Description 
40EQ5D 
 
Generic health outcome instrument that provides a simple descriptive profile and a single index value or utility score for health 
status. It comprises 5 dimensions: mobility, self-care, usual activities, pain /discomfort and anxiety /depression. Each dimension 
has a 3 category response scale: no problems, some problems, extreme problems. 
41EORTC  C30 
 
30 item, generic cancer questionnaire that consists of five function scales (physical, role, emotional, cognitive and social, a 
global health scale, three multi item symptom scales (fatigue, nausea/vomiting and pain) and six single item scales 
(dyspnoea, sleep, appetite, constipation, diarrhoea, and financial difficulties due to disease). Response categories have 4 
levels from ‘not at all’ to ‘very much’ apart from 2 items for overall physical condition and quality of life which use a 7 point 
scale. All scores from the scales and single item measures range from 0 to 100. A high scale score for global health status 
represents better quality of life 
42PR25 
 
Supplemental module to use in combination with the EORTC C30 for prostate specific issues (PR25) consisting of 25 items 
assessing urinary and bowel symptoms, sexual activity and functioning and side effects of therapy.  
43FACT P 
 
Comprises a generic core questionnaire (FACT-G) that comprises 27 items divided into 4 domains; physical, functional, 
emotional and social well-being. There is an additional subscale (FACT-P) with 12 prostate related specific concerns. All 
items are rated on a Likert scale from 0 to 4. The questionnaire produces an overall QoL score (FACT total) and subscale 
scores. Higher sum scores indicate a better quality of life.  Summation of the physical, functional and prostate subscale 
scores produces a Treatment Outcome Index (FACT-TOI), which is considered the most sensitive indicator of patient related 
health in treatment RCTs. 
44BPI-SF 
 
The BPI-SF (9 items) recommended for use in clinical trials. It assesses pain intensity and the interference of pain with daily 
life. There is no scoring algorithm, but "worst pain" or the arithmetic mean of the 4 severity items is used to assess pain 
severity. Pain intensity is recorded as the worst pain in the past 24 hours. Pain interference is the mean score of all 7 items 
assessing the impact of pain on emotional well-being and physical activity providing an overall interference score. 
45McGill-Melzack 
 
Used by patients to monitor their pain over time and to determine the effectiveness of any intervention. It comprises 78 
words, from which respondents choose those that best describe their pain experience. Scores are tabulated by summing 
values associated with each word; scores range from 0 (no pain) to 78 (severe pain). 
46McCaffery VAS  
 
This is a unidimensional visual analogue scale rating for pain, with 0 representing no pain and 10, pain that is intolerable 
47BFI 
 
The Brief Fatigue Inventory (BFI) assesses the severity and impact of cancer-related fatigue and its impact on daily 
functioning in the past 24 hours. Patients complete visual analogues scales from 0-10 rating their fatigue right now, usual 
fatigue, and worst in past 24 hours, followed by the interference of fatigue on general activity, mood, walking, work, 
relationships, and enjoyment of life. A global fatigue score is obtained by averaging all the items on the BFI.  
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Table 2: The effects of mCRPC treatments on QoL and pain palliation by drug  
Author 
Year 
 
Design and population Measures & time points Main Findings   
 
Comments 
ENZALUTAMIDE 
21Fizazi et 
al. 2014 
 
 
AFFIRM Phase III RCT 
enzalutamide (E)  
v placebo (PL) 
following chemotherapy  
N=674 E 
N= 264 PL 
BPI-SF Change from baseline 
to week 13  
 
FACT-P Overall QoL, on 
individual domains & time to 
deterioration 
Pain progression at week 13 for 
174/625 (28%) E v 101/259 
(39%) PL p=0.0018. Mean 
treatment effects for pain severity 
and interference were sig better 
with E than PL. 22/49 (45%) E 
reported pain palliation at week 
13 v 1/15 (7%) PL p=0.0079. 
Overall improvement in HRQoL 
in E 275/625 [42%] than Pl 
(36/248 [15%]; p<0.0001). 
Patients in the E had longer 
median time to HRQoL 
deterioration than PL p<0.0001. 
Excellent example of 
reporting QoL data with 
detailed analyses 
22Cella et al. 
2015 
 
 
AFFIRM Phase III RCT 
As above 
FACT-P completed before 
randomisation & at weeks 13, 
17, 21, 25 & every 12 weeks 
while on study 
 
 
 
After 25 weeks, the mean FACT-
P total score decreased by 1.52 
points with E compared with PL 
13.73 points (P < 0.001). 
Significant treatment differences 
at week 25 favouring E were 
evident for all FACT-P subscales 
and indices. 
Excellent example of 
reporting QoL data, 
reference to missing 
data. Used cumulative 
distribution function 
plots (CDF) in analysis. 
23Loriot et 
al. 2015 
 
PREVAIL Phase III RCT 
double-blind, placebo-
controlled trial of 
enzalutamide (E) 
 
N=872 E   
N=845 PL 
FACT-P baseline & during 
treatment 
EQ5D + VAS baseline & 
during treatment 
BPI-SF – baseline, weeks 13 
& 25  
Median time to deterioration in 
FACT-P total score 11.3mths (E) 
v 5.6mths (PL) (p<0.0001). 
Clinically meaningful 
improvements in FACT-P for E. 
EQ-5D & VAS showed sig. 
increase in proportion of patients 
Excellent reporting of 
how PRO data handled 
and analysed 
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in E than PL in time to worst pain 
longer in E than PL (p<0.0001). 
 
ABIRATERONE 
24Logothetis 
et al. 2012 
 
 
 
 
Phase III RCT (COU-
AA-301) double-blind, 
placebo-controlled trial 
of abiraterone + 
prednisone (AP) v 
placebo + prednisone 
(PP) post-docetaxel 
treatment 
 
N=797 AP 
N=398 PP 
BPI-SF at screening 
(baseline), day 15 of cycle 1, 
and day 1 of every 
subsequent treatment cycle 
until the end of study 
treatment 
Patients with clinically significant 
pain at baseline, AP resulted in 
sig palliation (157/ 349 [45%] vs 
47/163 [28·8%]; p=0·0005) and 
faster palliation (median time to 
palliation 5·6 months vs 13·7 
months p=0·0018) of pain 
intensity than PP. 
Good exploratory 
analysis of pain data 
with skeletal related 
events. Prospectively 
defined response 
criteria that also 
included analgesic use. 
25Harland et 
al. 2013 
 
 
QoL aspect of Phase III 
RCT (COU-AA-301)  
As above 
FACT-P at baseline and on 
day 1 of cycles 1, 4, 7, 10 & 
every six cycles until end of 
study treatment 
 
Significant improvements FACT-
P total score in 48% AP v 32% 
PP patients (p < 0.0001).  
Median time to deterioration in 
FACT-P total score was longer (p 
< 0.0001) for AP. Similar 
differences were observed in all 
FACT-P subscales, with the 
exception of the social/family 
well-being domain. Median time 
to improvement in the physical 
well-being domain and the trial 
outcome index was significantly 
shorter (p < 0.01) with AP. 
Only patients with 
impaired HRQoL 
considered for the 
improvement analyses. 
Could have shown 
numbers who 
improved, declined or 
stayed the same over 
time. Highlights need 
for more frequent 
assessments. 
26Sternberg 
et al. 2013 
 
 
Phase III RCT (COU-
AA-301)  
As above 
Brief Fatigue Inventory at 
baseline (∼14 days before the 
first dose of study treatment) 
& first day of each treatment 
cycle until treatment 
discontinuation 
Compared with PP patients with 
clinically significant fatigue at 
baseline, AP significantly 
increased proportion reporting 
improvement in fatigue intensity 
(58% v 40%, P = 0.0001), 
improved fatigue interference 
(55% v 38%, P = 0.0075), & 
Good paper but again 
analyses confined to 
those with fatigue at 
baseline. 
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accelerated improvement in 
fatigue intensity (P = 0.0155). 
27Basch et 
al. 2013 
 
 
Phase III (COU-AA-302) 
double blind placebo 
controlled trial of 
abiraterone + 
prednisone (AP) v 
placebo + prednisone 
(PP) in chemo naïve 
patients 
 
N= 546 (AP) 
N=542 (PP) 
BPI-SF at screening, day 1 of 
each treatment cycle & at 
treatment end. 
FACT-P first day of cycles 1, 
3, 5, 7 & then first day of 
every 3rd cycle & at treatment 
discontinuation.  
Median times to progression of 
worst pain intensity were similar 
between groups. Median time to 
mean pain intensity also was 
longer with AP (p=0.049) and 
median time to interference with 
daily activities (p=0.005). AP 
significantly delayed time to QoL 
deterioration compared with PP, 
as assessed by FACT-P total 
score, general function and trial 
outcome index composite scores, 
prostate-cancer-specific scores, 
and all subscale scores except 
for social and family wellbeing 
(p<0.001).  
Good reporting of data 
from BPI but only 
reported overall QoL 
scores. 
DOCETAXEL 
28Caffo et al. 
2011 
 
 
Phase II RCT docetaxel 
(DOC) +/- estramustine 
N=95 mCRPC 
EORTC QLQ C30 
BPI & analgesia use at 
baseline & after every two 
DOC courses 
The patients completing at 
least 2 questionnaires (at 
baseline and before the 3rd 
course) were considered 
evaluable 
59/79 included in stats. 
Asymptomatic patients and 
responders had better baseline 
QoL than symptomatic patients 
and non-responders. No 
significant changes in QLQ-C30 
scales during treatment except 
patients receiving DOC and 
estramustine, who experienced a 
significant decrease in pain. 
However big drop in completion 
of questionnaires across time. 
 
Important study as it 
can identify responders 
from baseline 
assessment. Also 
reported proportions of 
patients who improved, 
remained stable and 
worsened from 
baseline.  
29Caffo et al. 
2015 
 
 
RCT of continuous v 3 
monthly intermittent 
DOC  
N=75 continuous 
N=73 intermittent 
EORTC QLQ C30 at baseline 
then every 2 courses 
BPI-SF used a difference of 2 
points to assess either 
improvement or deterioration 
in pain 
Failed to show any significant 
differences in QoL or pain 
between the groups possibly due 
to timing of assessments. 
 
 
 
Not very detailed  
reporting of QoL data, 
no details of number of 
completed 
questionnaires across 
time 
March 30th 2016 Clean Revision  
 
17 
 
CABAZITAXEL 
30Bahl et al. 
2013 
 
 
 
Follow up on subgroup 
of patients who survived 
>2 years in TROPIC 
(cabazitaxel v 
mitoxantrone) to 
examine pain palliation.  
N=60 cabazitaxel        
N=31 mitoxantrone 
McGill-Melzack pain 
questionnaire. Pain response 
& progression pre-specified 
end points. Pain assessed 
before each treatment cycle 
then every 6 weeks during the 
first 6 months of follow up & 
every 3 months thereafter 
until progression or initiation 
of other anticancer therapy. 
No significant differences in pain 
progression or pain response 
between treatment groups, 
possibly due to small numbers.  
ECOG used as a measure of 
QoL –it is a performance score 
completed by the physician, not 
by the patient. 
Poor reporting of data, 
small numbers, 
retrospective analysis, 
no reporting of missing 
data or data on number 
of questionnaires 
completed over time.  
 
31Bahl et al. 
2015 
 
 
Phase III/IV trial to 
facilitate access to 
cabazitaxel and formal 
QoL evaluation  
N =112 mCRPC 
EQ5D-3L with VAS at 
baseline, alternate cycles & 
end of treatment. Mean 
scores and paired analyses 
for EQ5D and also reported 
pain statement changes. 
No formal statistical analyses 
conducted but report a trend to 
improved QoL at week 10 from 
baseline. Large error bars. 
Poor reporting of QoL 
data, poor choice of 
instrument. The EQ5D 
is more used for 
economic analysis of 
treatments.  
 
 
 
RADIOISOTOPES 
32Nilson et 
al. 2012 
 
Phase II study of radium 
-223 chloride for 
palliation N=100 
mCRPC 
BPI  
VAS for pain index  
1 week diary of daily baseline 
pain on VAS and patients’ 
record of analgesic use and 
BPI  
Change from baseline at 
weeks 2, 4, 8, 12,16  
Patients categorised as 
responders or non-responders. 
Dose dependent treatment effect. 
71% pain response two weeks 
after administration. 
Good example of use 
of BPI to measure pain 
but no other PRO data. 
33Agarwal et 
al. 2015 
 
 
 
Phase II RCT trial of 
high v low dose 177Lu-
EDTMP for bone pain 
relief in patients with 
bone metastases 
N=32 mCRPC 
N=12 breast 
Daily diary 
McCaffery visual analogue 
pain scale, Pain relief 
assessed in terms of changes 
in average baseline pain v 
average scores at 
1,2,4,5,7,12 and 16 weeks 
Karnofsky performance 
score (KPS) to measure QoL  
177Lu-EDTMP safe and effective 
alternative for bone pain 
palliation in patients with 
metastatic disease. 
Progressive decrease in pain on 
the VAS from baseline up to 4 
weeks. 
Also improvement in QoL on the 
KPS but it is not a PRO. 
Poor choice of 
instrument to measure 
QoL (the KPS), also a 
very small sample and 
little information about 
data handling. 
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DENOSUMAB 
34Von-Moos 
et al. 2013 
 
 
Pooled data analysed 
from 3 identically 
designed double-blind 
phase III trials 
comparing sc 
denosumab 120 mg 
with IV zoledronic acid 4 
mg monthly in patients 
with bone metastases 
from cancer 
 
N =2,046 breast              
N =1,901 mCRPC 
N=1,597 solid tumours. 
BPI-SF for pain severity 
analyses. A score of ≤4 was 
considered no or mild pain 
and scores of >4 considered 
moderate to severe pain. 
7 items from the BPI-SF 
measured pain interference 
with general activity, walking, 
work, mood, enjoyment of life, 
relations with others and 
sleep. FACT-G also 
completed at each monthly 
visit 
Denosumab significantly delayed 
time to increase in pain by 0.3 
months in those with pain at 
baseline and delayed pain by 1.8 
months in those with no/mild pain 
at baseline. HRQL – FACT G 
MIDs.  
 
Fewer denosumab treated 
patients experienced clinically 
meaningful worsening from 
baseline. 
Good analyses but 
pooling of data across 
cancer sites makes it 
difficult to determine 
exactly the benefits for 
mCRPC patients 
 
 
